The Early Use of Long-acting Injectable Antipsychotic Drugs in the Treatment of Bipolar Disorder: A Call for Action

The Early Use of Long-acting Injectable Antipsychotic Drugs in the Treatment of Bipolar Disorder: A Call for Action

Saved in:

Bibliographic Details
Main Author:	Shih-Ku Lin
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2025-04-01
Series:	Taiwanese Journal of Psychiatry
Online Access:	https://journals.lww.com/10.4103/TPSY.TPSY_15_25
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Procyclidine Use with Long-Acting Injectable Antipsychotics
by: Prabin Gautam, et al.
Published: (2025-06-01)

Procyclidine Use in Long-Acting Injectable Antipsychotics
by: Shalina Mitchell, et al.
Published: (2025-06-01)

Long-acting injectable antipsychotics for early psychosis: A comprehensive systematic review.
by: Lulu Lian, et al.
Published: (2022-01-01)

Subjective well-being in early-phase schizophrenia patients using long-acting injectable vs. oral antipsychotic drugs: data from the European Long-acting Antipsychotics in Schizophrenia Trial (EULAST)
by: Anna-Theresa Schulze, et al.

Using Extended-Release Injectable Aripiprazole for the Successful Treatment of Depressive Symptoms in Bipolar I Disorder
by: Joseph Kuo, et al.
Published: (2020-01-01)

Long-Acting Antipsychotic Injections: Prescribing Practices Across BCUHB
by: Laura Robbins, et al.
Published: (2025-06-01)

The evolution of long-acting antipsychotic treatments
by: Sofia Pappa, et al.
Published: (2024-12-01)

Comparative Analysis of Time to All-cause Treatment Discontinuation and Rehospitalization among Early-phase Schizophrenia Patients Discharged on Long-acting Injectable Antipsychotics versus Oral Antipsychotics
by: Ta-Chun Lin, et al.
Published: (2025-01-01)

Drug utilization study of mood stabilizers and antipsychotics drugs among bipolar disorder patients
by: Lolita Lolita, et al.
Published: (2024-01-01)

Second-generation long-acting injectable antipsychotics in schizophrenia: patient functioning and quality of life
by: Montemagni C, et al.
Published: (2016-04-01)

Long-Acting Injectable Antipsychotic Use in Patients with Schizophrenia and Criminal Justice System Encounters
by: Madhav P. Bhatta, et al.
Published: (2021-05-01)

Aripiprazole Lauroxil: Development and Evidence-Based Review of a Long-Acting Injectable Atypical Antipsychotic for the Treatment of Schizophrenia
by: Citrome L, et al.
Published: (2025-03-01)

Do Long-Acting Injectable Antipsychotics Influence Serum Levels of Brain-Derived Neurotrophic Factor in People With Schizophrenia and Schizoaffective Disorder?
by: Mirko Manchia, et al.
Published: (2024-01-01)

Financial incentives and long-acting injectable antipsychotics engagement: community mental health professionals’ perspectives
by: Nathan Hodson, et al.
Published: (2025-08-01)

Comparative modelling of foetal exposure to maternal long-acting injectable versus oral daily antipsychotics
by: Philip Bediako-Kakari, et al.
Published: (2025-05-01)

Perspectives on Precision Psychiatry Using Antipsychotics in the Management of Bipolar Disorder
by: Michele Fornaro, et al.
Published: (2025-04-01)

Clinical Utility of Long-Acting Injectable Risperidone in Schizophrenia and Bipolar I Disorder: A Review of Clinical Studies
by: Bartoli F, et al.
Published: (2025-06-01)

Enhanced treatment outcomes for schizophrenia through combined long-acting injectable antipsychotic medications and home visits: retrospective cohort study
by: Hiroyuki Harada, et al.
Published: (2025-09-01)

Two Long-Acting Antipsychotics in a Patient with Treatment-Resistant Schizophrenia: A Case Report
by: Salvatore Cipolla, et al.
Published: (2025-03-01)

Unraveling disordered eating: a call for early intervention and action
by: Stella Nabuco Nasser, et al.
Published: (2025-07-01)

Population Pharmacokinetic Modeling of TV-46000, a Risperidone Long-Acting Subcutaneous Antipsychotic for the Treatment of Patients with Schizophrenia
by: Itay Perlstein, et al.
Published: (2025-03-01)

Unveiling the Future: Opportunities in Long-Acting Injectable Drug Development for Veterinary Care
by: HariPriya Koppisetti, et al.
Published: (2025-05-01)

The Importance of Antipsychotic Treatment in Severe Mental Disorders
by: Pasquale Paribello, et al.
Published: (2025-03-01)

Chemoprevention of malaria with long-acting oral and injectable drugs: an updated target product profile
by: Myriam El Gaaloul, et al.
Published: (2024-10-01)

Retrospective cohort study of long-acting injectable (LAI) antipsychotic initiation in the inpatient setting: impact of LAI characteristics on transition and continuation of care among patients with schizophrenia in the USA
by: Rashmi Patel, et al.
Published: (2025-03-01)

Post Mortem Paliperidone Blood Concentrations Following Long-Acting Injectable Treatments
by: Pietro Zuccarello, et al.
Published: (2025-05-01)

Therapeutic drug monitoring of atypical antipsychotic drugs
by: Grundmann Milan, et al.
Published: (2014-12-01)

Following the Action of Atypical Antipsychotic Clozapine and Possible Prediction of Treatment Response in Schizophrenia
by: Mihai-Gabriel Năstase, et al.
Published: (2025-05-01)

Earlier Use of Long-Acting Injectable Paliperidone Palmitate Once-Monthly versus Oral Antipsychotics in Patients with Schizophrenia: An Integrated Patient-Level Meta Analysis of the PROSIPAL and PRIDE Studies [Corrigendum]
by: Sajatovic M, et al.
Published: (2025-06-01)

Use of Aripiprazole Long Acting Injection in Negative Symptoms of Schizophrenia
by: Suneeta James, et al.
Published: (2016-01-01)

Preparation and Evaluation of Long-Acting Injectable Levocetirizine Prodrug Formulation
by: Jun-hyun Ahn
Published: (2025-06-01)

Long-acting injectable biologics: a game-changer in immunopharmacology
by: Ayat Abdulkhaleq Jawad, et al.
Published: (2025-08-01)

Re: Hernandez Bustamante et al. “Pharmacist administration of long-acting injectable medications for substance use disorders”
by: Jerry McKee, PharmD, MS, BCPP, et al.
Published: (2025-08-01)

Combined Audit for depot/LAI (Long-Acting Injectable) Antipsychotic Medications Relapse Prevention and Side Effects for Older Adult Populations (Pan Trust Audit – Black Country Healthcare NHS Foundation Trust)
by: Sui Yung Chen, et al.
Published: (2025-06-01)

Application of screening techniques for early diagnostics of bipolar afapplication of screening techniques for early diagnosis of a risk of bipolar disorder in adolescents
by: N. N. Osipova, et al.
Published: (2022-07-01)

Challenges in the development of treatment guidelines for bipolar disorder
by: Konstantinos N. Fountoulakis, et al.
Published: (2025-06-01)

Risk management of metabolic disorders in the use of antipsychotics
by: G. E. Mazo, et al.
Published: (2018-07-01)

A call to action for adverse drug event (ADE) detection and prevention
by: John McCue, et al.
Published: (2025-03-01)

A Call to Action: Empowering Pharmacists in Drug-Resistant Tuberculosis Management
by: Alfaqeeh M, et al.
Published: (2025-06-01)

The long odyssey for the DEE‐CDKL5 diagnosis: A call for action
by: Kette D. Valente, et al.
Published: (2024-12-01)